Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Recursion Pharmaceuticals Inc Cl A
(NQ:
RXRX
)
7.810
+0.460 (+6.26%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Recursion Pharmaceuticals Inc Cl A
< Previous
1
2
Next >
Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference
January 08, 2024
Recursion and NVIDIA will host an invite-only event on Wednesday, January 10, where Recursion will provide live demonstrations of LOWE, its new LLM-based software that can perform complex drug...
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
January 04, 2024
Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Recursion to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
January 03, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry
December 20, 2023
Screening libraries will leverage Recursion's MatchMaker tool to identify compounds across Enamine REAL Space predicted to bind to high-value targets.
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Unlocking AI investment opportunities in healthcare
November 16, 2023
AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities.
Via
MarketBeat
Topics
Artificial Intelligence
ETFs
Exposures
Artificial Intelligence
Bayer and Recursion Focus Research Collaboration on Oncology
November 09, 2023
Digitally enabled drug discovery for oncology has the potential to accelerate the delivery of new cancer therapies to patients. Drug discovery research collaboration may initiate up to seven oncology...
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
November 09, 2023
With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conference
November 02, 2023
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
September 05, 2023
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
September 05, 2023
REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent...
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
August 08, 2023
Recursion has predicted the protein target(s) for approximately 36 billion chemical compounds in the Enamine REAL Space, reported to be the world’s largest searchable chemical library. These advances...
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conference
August 01, 2023
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
August 01, 2023
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Biotech & Healthcare Meet AI: Stocks Soar On Innovation Potential
July 28, 2023
A growing number of companies in the biotech and healthcare industries are using AI to revolutionize drug discovery and patient care, leading to stock surges.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Exscientia is the Sniper of the AI Drug Discovery Industry
July 27, 2023
News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA) into AI-powered drug discovery company Recursion
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships
July 26, 2023
Valence Labs is Recursion’s new machine learning research center that aims to promote open science and academic research. $1 million will be committed to advancing the next generation of academic...
From
Recursion Pharmaceuticals
Via
GlobeNewswire
MarketBeat Week in Review – 7/17 - 7/21
July 22, 2023
Investor sentiment remains strong but upcoming tech earnings and an expected interest rate hike may provide more clarity on the short-term outlook for stocks
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Nvidia Invested $50 million into This AI Drug Discovery Biotech
July 17, 2023
Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Recursion Pharmaceuticals (NASDAQ: RXRX) Forms Powerful Partnership with NVIDIA (NASDAQ: NVDA)
July 12, 2023
A $50 Million Investment to Boost AI Capabilities in Drug Discovery Recursion Pharmaceuticals (NASDAQ: RXRX), a trailblazer in TechBio that
Via
Spotlight Growth
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
July 12, 2023
Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments faster
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Celebrates Opening of Its Canadian Headquarters in Toronto with Government Officials and the Biotech Ecosystem
June 26, 2023
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled
June 13, 2023
Recursion's small molecule is the first therapeutic candidate to be advanced to an industry-sponsored Phase 2 clinical trial for cerebral cavernous malformation (CCM). CCM is a devastating...
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
June 01, 2023
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
May 16, 2023
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results
May 08, 2023
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities
May 08, 2023
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
May 02, 2023
From
Recursion Pharmaceuticals
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.